Integrated FHIT and IDH2 biomarker profiling predicts lethal sensitivity to DCPS inhibition in Acute Myeloid Leukemia and Myelodysplastic syndrome

Abstract Background/objectives Development of novel therapies for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) is hindered by limited biomarkers to identify appropriate target populations and poor translatability of preclinical drug candidates. In this study, we sought to validate...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Francesca Grassi, Lisa Bast, Madhurendra Singh, Magnus Tobiasson, Julian Walfridsson, Angelo de Milito, Martin Andersson, Andreas Höglund
Format:	Artigo
Jezik:	Inglês
Izdano:	Springer 2026-03-01
Serija:	Discover Oncology
Online dostop:	https://doi.org/10.1007/s12672-026-04880-x
Oznake:	Označite Brez oznak, prvi označite!